Publications by authors named "Srishti Suresh Jain"
Article Synopsis
- The study investigates the effectiveness of ulinastatin, a urinary trypsin inhibitor, in treating COVID-19 patients who experience end-organ damage linked to inflammatory responses.
- Researchers analyzed data from 736 hospitalized patients over a month, using propensity score matching to compare outcomes between a control group and those receiving ulinastatin.
- The results showed no significant differences in ICU length of stay or in-hospital mortality rates between the two groups, highlighting the need for larger, randomized controlled trials to further assess the potential benefits of ulinastatin therapy in COVID-19 treatment.
Introduction: COVID-19 patients are categorized as per their clinical severity and their level of care is decided based on the clinical severity. Apart from clinical severity of patients, a need for robust predictors was also felt for early categorization and accurate prediction of final fatal outcome in hospitalized patients.
Material And Method: In this retrospective observational cohort study all the adult patients admitted during November month were included.